The purpose of this research was to assess the safety and effectiveness of IDH1,IDH2 Gene Mutation Sequencing in gliomas. A systematic review was conducted to identify relevant articles published until 2011 April. The SIGN (Scottish Intercollegiate Guidelines Network) checklists were used for critical appraisal. After data extraction, meta analysis or descriptive analysis was carried out. The tests are conducted outside the body using tumor tissues. A ccordingly, there was no safety issue. Effectiveness of the test was assessed by 27 articles. IDH2 mutations (15 studies) were detected in the range of 0-5.8%. In diagnosis of gliomas, IDH1 gene mutation test had pooled sensitivity of 0.18 and pooled specificity
of 1.00. If there was IDH1 or IDH2 gene mutation, survival rate was higher and survival period was significantly longer (overall survival : median value 18.0- 150.9 months vs. 8.6-83.9 months). Although one study reported that the response
rate was high if there was IDH1 or IDH2 gene mutation, the other 3 studies reported that IDH1 gene mutation was irrelevant to chemotherapy response. In conclusion, IDH1 Gene Mutation Sequencing was assessed to be a safe and an effective biomarker for diagnosis and prognosis of gliomas. However, more studies are needed to evaluate its effectiveness as a predictive biomarker for gliomas. On the contrary, IDH2 Gene Mutation Sequencing, although s afe, did not provide additional information due to low occurrence of IDH2 gene mutation in gliomas.
|